Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index; 51 of the 251 sources its claims cite were checked for support.

Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration

Open access
Gómez de San José, Nerea, Massa, Federico, Halbgebauer, Steffen, Oeckl, Patrick, Steinacker, Petra, Otto, Markus · 2022 · Journal of Neural Transmission

Abstract

The diagnosis of neurodegenerative disorders is often challenging due to the lack of diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction is an early pathological event in many neurodegenerative disorders, but the underpinning mechanisms are still poorly characterised. Reliable quantification of synaptic damage is crucial to understand the pathophysiology of neurodegeneration, to track disease status and to obtain prognostic information. Neuronal pentraxins (NPTXs) are extracellular scaffolding proteins emerging as potential biomarkers of synaptic dysfunction in neurodegeneration. They are a family of proteins involved in homeostatic synaptic plasticity by recruiting post-synaptic receptors into synapses. Recent research investigates the dynamic changes of NPTXs in the cerebrospinal fluid (CSF) as an expression of synaptic damage, possibly related to cognitive impairment. In this review, we summarise the available data on NPTXs structure and expression patterns as well as on their contribution in synaptic function and plasticity and other less well-characterised roles. Moreover, we propose a mechanism for their involvement in synaptic damage and neurodegeneration and assess their potential as CSF biomarkers for neurodegenerative diseases.

Overview

CoChat Summary

TL;DR

This review summarizes neuronal pentraxins (NPTX1, NPTX2, NPTXR) as synaptic organizer proteins and candidate CSF biomarkers of synaptic dysfunction in neurodegeneration. It proposes that NPTX changes may track early synaptic damage and cognitive decline, but current evidence is heterogeneous and mostly limited to CSF.

Key findings

  • NPTXs are extracellular scaffolding proteins in the synaptic cleft; NPTX1 and NPTX2 form heteromultimers, bind NPTXR, and cluster/stabilize AMPAR at excitatory synapses onto parvalbumin interneurons. NPTX1 and NPTX2 show opposite activity-dependent regulation: NPTX1 is linked to low activity, apoptosis, and complement-mediated pruning, whereas NPTX2 is activity/BDNF-dependent and promotes plasticity. NPTXR knockout mice had 50% reduced brain NPTX1 and NPTX2 levels.
  • In AD CSF, NPTX2 is decreased in MCI and AD versus controls; NPTX2 ratio with tau or p-tau showed the best performance to discriminate AD from controls, and NPTX2 predicted progression and correlated with cognition, medial temporal atrophy, and hippocampal volume. NPTX1 and NPTXR showed a biphasic pattern—elevated in MCI/early stages and decreased in dementia—with NPTXR declining by about 6.9%/year, 6.7%/year, or 10%/year in AD; NPTXR discriminated advanced AD from MCI with AUC = 0.799.
  • In genetic and sporadic FTLD, NPTX1, NPTX2, and NPTXR were decreased in symptomatic mutation carriers versus pre-symptomatic carriers/non-carriers; NPTX2 had AUC = 0.71, comparable to neurogranin, and declined over time in symptomatic and pre-symptomatic carriers over age 50. In DLB, CSF NPTX2 was lower than in controls and correlated with visuospatial cognition; NPTX2 was highly upregulated in PD substantia nigra and accumulated in Lewy bodies.
  • Proposed pathological mechanisms include astrocyte dysfunction and reduced BDNF lowering NPTX1/NPTX2 release, low neuronal activity driving NPTX1 mitochondrial BAX-dependent apoptosis, impaired TACE/NPTXR cleavage contributing to excitotoxicity, and intensified complement-microglia synaptic pruning.

Methods

  • Narrative review of published literature on NPTX structure, expression patterns, physiological synaptic roles, and proposed involvement in synaptic damage and neurodegeneration.
  • Summarizes CSF biomarker studies in AD and FTLD in Table 2, plus studies in synucleinopathies, psychiatric disorders, epilepsy, stroke, neuroinflammatory diseases, and brain tumors; cited measurement methods include mass spectrometry, ELISA, Western blot, and antibody suspension bead array.
  • No primary cohort or meta-analysis is reported; the paper synthesizes existing studies and proposes mechanistic models.

Limitations

  • Stated: reliable NPTX measurements can currently only be performed in CSF due to insufficient assay sensitivity in blood; lumbar puncture is invasive, so longitudinal studies are missing; lack of consistency between studies may result from different inclusion/exclusion criteria and absence of standardized analytical methods; prospective studies are required.
  • Stated: observed NPTX alterations reflect a general pathological pattern rather than a disease-specific mechanism, and their suitability for clinical diagnostic purposes requires further investigation.
  • Evident: this is a narrative rather than systematic review, and many cited studies are small, cross-sectional, and use heterogeneous assays, which the authors note may explain contradictory NPTX1/NPTXR findings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00702-021-02411-2

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 a Sequence localisation of the protein domains of pentraxins: pentraxin domain (purple), signal peptide (green), coiled coil region (blue), low complexity region (red) and transmembrane domain (orange). Long pentraxins (PTX3—P26022, PTX4—Q96A99, NPTX1—Q15818, NPTX2—P47972 and NPTXR—O95502) share the C-terminal pentraxin domain with short pentraxins (CRP—P02741 and SAP—P02743), but they contain a long N-terminal domain. Data obtained from Proteomics DB and UniProt. Created with Biorender.com b Experimental quaternary structure of the pentameric human CRP and SAP obtained by X-Ray diffraction. Data obtained from the Swiss-Model database (Emsley et al. 1994; Shrive et al. 1996; Waterhouse et al. 2018) c Tertiary structure of the pentraxin domain of all members of the pentraxin family. Experimental tertiary structure of the pentraxin domain of CRP, SAP and NPTX1 obtained by X-Ray diffraction, two-layered β sheet with a flattened jellyroll topology (Emsley et al. 1994; Shrive et al. 1996; Suzuki et al. 2020). Predicted structure of the pentraxin domain of PTX3, PTX4 and neuronal pentraxins (NPTX1, NPTX2 and NPTXR) by sequence homology with NPTX1. The pentraxin domain is highly conserved within this family of proteins. Data obtained from the Swiss-Model database. d Tertiary structure of the NPTXs obtained with the Protein Structure Database AlphaFold (Senior et al. 2020). The colour code indicates the per-residue confidence score (0–100): dark blue (> 90, very high), light blue (90–70, confident), yellow (70–50, low), orange (< 50, very low)
Fig. 1 a Sequence localisation of the protein domains of pentraxins: pentraxin domain (purple), signal peptide (green), coiled coil region (blue), low complexity region (red) and transmembrane domain (orange). Long pentraxins (PTX3—P26022, PTX4—Q96A99, NPTX1—Q15818, NPTX2—P47972 and NPTXR—O95502) share the C-terminal pentraxin domain with short pentraxins (CRP—P02741 and SAP—P02743), but they contain a long N-terminal domain. Data obtained from Proteomics DB and UniProt. Created with Biorender.com b Experimental quaternary structure of the pentameric human CRP and SAP obtained by X-Ray diffraction. Data obtained from the Swiss-Model database (Emsley et al. 1994; Shrive et al. 1996; Waterhouse et al. 2018) c Tertiary structure of the pentraxin domain of all members of the pentraxin family. Experimental tertiary structure of the pentraxin domain of CRP, SAP and NPTX1 obtained by X-Ray diffraction, two-layered β sheet with a flattened jellyroll topology (Emsley et al. 1994; Shrive et al. 1996; Suzuki et al. 2020). Predicted structure of the pentraxin domain of PTX3, PTX4 and neuronal pentraxins (NPTX1, NPTX2 and NPTXR) by sequence homology with NPTX1. The pentraxin domain is highly conserved within this family of proteins. Data obtained from the Swiss-Model database. d Tertiary structure of the NPTXs obtained with the Protein Structure Database AlphaFold (Senior et al. 2020). The colour code indicates the per-residue confidence score (0–100): dark blue (> 90, very high), light blue (90–70, confident), yellow (70–50, low), orange (< 50, very low)CC BY · PubMed Central
Fig. 2 2D representation according to axial, coronal and sagittal axes and 3D rendering of the areas with the highest RNA expression of NPTX1 (a), NPTX2 (b) and NPTXR (c). The gene expression data was obtained from Allen Human Brain Atlas (Hawrylycz et al. 2012). Microarray analysis of 900 anatomically defined sites of 6 patients was conducted with two different probes. The areas with a z score > 1 were considered. Regions of interest were obtained by MarSBar toolbox (Brett et al. 2002) to be overlaid to the MNI referential atlas (MRIcroGL software, https://www.nitrc.org/projects/mricrogl) and are represented in different colours, as follows: frontal lobe (wine red), temporal lobe (purple), amygdala (light blue), hippocampus (black), cerebellum (copper), thalamus (brown), occipital-temporal gyrus (green), insula (orange), parietal lobe (yellow), cingulate gyrus (dark blue) and parahippocampal gyrus (red). Anatomical positions: anterior (A), posterior (P), superior (S), inferior (I), left (L) and right (R)
Fig. 2 2D representation according to axial, coronal and sagittal axes and 3D rendering of the areas with the highest RNA expression of NPTX1 (a), NPTX2 (b) and NPTXR (c). The gene expression data was obtained from Allen Human Brain Atlas (Hawrylycz et al. 2012). Microarray analysis of 900 anatomically defined sites of 6 patients was conducted with two different probes. The areas with a z score > 1 were considered. Regions of interest were obtained by MarSBar toolbox (Brett et al. 2002) to be overlaid to the MNI referential atlas (MRIcroGL software, https://www.nitrc.org/projects/mricrogl) and are represented in different colours, as follows: frontal lobe (wine red), temporal lobe (purple), amygdala (light blue), hippocampus (black), cerebellum (copper), thalamus (brown), occipital-temporal gyrus (green), insula (orange), parietal lobe (yellow), cingulate gyrus (dark blue) and parahippocampal gyrus (red). Anatomical positions: anterior (A), posterior (P), superior (S), inferior (I), left (L) and right (R)CC BY · PubMed Central
Fig. 3 Schematic illustration of the proposed mechanism for the physiological role of neuronal pentraxins (NPTXs) (a) and the hypothesised pathological mechanisms in neurodegeneration (b). a The NPTX1 release from the pre-synaptic terminal into the synaptic cleft may be modulated by the astrocyte-secreted glypican-4 (GPC4) (1), whereas NPTX2 is synthesize and release in response to neuronal activity or BNDF (2). Once in the synaptic cleft, NPTX1 and NPTX2 can form heterocomplexes and bind to NPXR, which is anchored in the post-synaptic membrane. The NPTX complex is then able to cluster and stabilise α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) in the post-synaptic membrane, modulating the excitatory drive onto parvalbumin (PV) interneurons (3). In the presence of excess of glutamate in the synaptic cleft, the mGLUR1/5 receptor is activated and the metalloprotease tumour necrosis factor-alpha converting enzyme (TACE) cleaves the transmembrane domain of NPTXR. Cleaved NPTXR and AMPAR are internalised via endocytosis. This mechanism may protect against excitotoxicity (4). NPTX1 may play a role as activator of the classical complement pathway, leading to microglia-dependent apoptosis (5). b Several hypotheses could explain the deregulation of NPTXs and the excess of synaptic loss observed in neurodegeneration. The loss of astrocytic functions and reduced BDNF could lead to a decrease in synthesis and release of NPTX1 and NPTX2, respectively (1, 2). Under low neuronal activity, NPTX1 translocates to the mitochondria, activating BAX-dependent apoptosis and hindering the translocation of mitochondria to the pre-synaptic terminal (3). An alteration of the mechanism to detect excess of glutamate could decrease the endocytosis of NPTX complexes, leading to excitotoxicity (4). The complement-microglia pathway activated by NPTX1 may be intensified upon neurodegenerative processes, favouring the excess synaptic loss observed in these disorders (5). Created with Biorender.com
Fig. 3 Schematic illustration of the proposed mechanism for the physiological role of neuronal pentraxins (NPTXs) (a) and the hypothesised pathological mechanisms in neurodegeneration (b). a The NPTX1 release from the pre-synaptic terminal into the synaptic cleft may be modulated by the astrocyte-secreted glypican-4 (GPC4) (1), whereas NPTX2 is synthesize and release in response to neuronal activity or BNDF (2). Once in the synaptic cleft, NPTX1 and NPTX2 can form heterocomplexes and bind to NPXR, which is anchored in the post-synaptic membrane. The NPTX complex is then able to cluster and stabilise α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) in the post-synaptic membrane, modulating the excitatory drive onto parvalbumin (PV) interneurons (3). In the presence of excess of glutamate in the synaptic cleft, the mGLUR1/5 receptor is activated and the metalloprotease tumour necrosis factor-alpha converting enzyme (TACE) cleaves the transmembrane domain of NPTXR. Cleaved NPTXR and AMPAR are internalised via endocytosis. This mechanism may protect against excitotoxicity (4). NPTX1 may play a role as activator of the classical complement pathway, leading to microglia-dependent apoptosis (5). b Several hypotheses could explain the deregulation of NPTXs and the excess of synaptic loss observed in neurodegeneration. The loss of astrocytic functions and reduced BDNF could lead to a decrease in synthesis and release of NPTX1 and NPTX2, respectively (1, 2). Under low neuronal activity, NPTX1 translocates to the mitochondria, activating BAX-dependent apoptosis and hindering the translocation of mitochondria to the pre-synaptic terminal (3). An alteration of the mechanism to detect excess of glutamate could decrease the endocytosis of NPTX complexes, leading to excitotoxicity (4). The complement-microglia pathway activated by NPTX1 may be intensified upon neurodegenerative processes, favouring the excess synaptic loss observed in these disorders (5). Created with Biorender.comCC BY · PubMed Central

Verification

Claims the paper makes

34 Valid · 1 Not valid · 129 Not checked · 26 Own results and interpretations

116 more claims · 24 with their cited sources checked

Create a free account to see all 190 claims and to verify the 200 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 22
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

1 retracted

Show all 181 references

Cited by

See all 115

Metadata

Authors
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M.
Affiliations
Universität Ulm (DE)
Corresponding author
Otto, Markus
Venue
Journal of Neural Transmission
Published
2021-08-30
Volume
129
Issue
2
Pages
207-230
ISSN
  • 0300-9564 (ISSN-L)
  • 1435-1463
OpenAlex
W3197743626
Cited by
112
References
181
Citations by year
2026: 24 · 2025: 36 · 2024: 31 · 2023: 12 · 2022: 9
FWCI
1.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neural Transmission (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
  • OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) (submittedVersion, other-oa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • Universität Ulm, Kommunikations- und Informationszentrum (kiz) (cc-by)
Funders
  • h2020 marie skłodowska-curie actions (860197)
  • Universität Ulm
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
synaptic dysfunction, neurodegeneration, cerebrospinal fluid biomarkers, synaptic plasticity, cognitive impairment, neurodegenerative disease diagnosis
MeSH terms
Pentraxins, C-Reactive Protein, Nerve Tissue Proteins, Neuronal Plasticity, Synapses, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. https://app.cochat.ai/papers/10.1007/s00702-021-02411-2
The paper
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022). Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. Journal of Neural Transmission. https://doi.org/10.1007/s00702-021-02411-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.